ERBB2 and breast carcinoma: Collectively, our results indicated that treatment of HER2-positive breast cancer cell lines (SKBR3 and ZR75) with compounds DK-13 and -14 inhibits cell invasion, thereby attenuating breast cancer progression through the impairment of cell invasion.